WP1732
/ UT MD Anderson Cancer Center, Mayo Clinic, WPD Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
August 16, 2019
Moleculin Biotech, Inc. reports financial results for the second quarter ended June 30, 2019
(PRNewswire)
- “Anticipated Milestones: Announcement of initial clinical data from WP1066 clinician sponsored trial - 2019; Phase 1 surgical cohort begins – 2020; Transfer clinician sponsored trial WP1066 IND to Moleculin - Second Half of 2019; Emory Physician Led Pediatric Medulloblastoma Trial begins - Second Half of 2019; Assess WP1220 initial patient data - Q4-2019; IND for WP1732 submitted – 2020; Dose first patient in Phase I trial for WP1732 – 2020; Complete formulation and begin manufacture of drug for trial - First Half of 2020; File IND for WP1122 – 2020.”
Clinical data • Enrollment status • IND • New trial
1 to 1
Of
1
Go to page
1